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Objective. This study examined whether glycated hemoglobin (HbA1c) and glycated albumin (GA) are well correlated with the 
Ankylosing Spondylitis Disease Activity Score (ASDAS)-erythrocyte sedimentation rate (ESR), and ASDAS-C-reactive protein 
(CRP) in AS patients without medical conditions affecting the glycated protein levels. Methods: The data of 76 patients with AS 
were analyzed. Univariate and multivariate analyses of the variables associated with ASDAS-ESR and ASDAS-CRP were per-
formed using a linear regression test. The patients were divided into active and inactive AS groups based on an ASDAS-CRP of 
2.1, and the variables between the two groups were compared. Results. ASDAS-ESR did not correlated with either HbA1c or 
GA. ASDAS-CRP was positively correlated with HbA1c (r=0.315, p=0.006) and the white blood cell (r=0.288, p=0.012), and 
inversely correlated with hemoglobin (r=−0.241, p=0.036) and serum albumin (r=−0.262, p=0.022), but not GA. 
Multivariate analysis revealed HbA1c and white blood cell to be significantly correlated with ASDAS-CRP (β=0.234, 
p=0.033 and β=0.265, p=0.017). The mean HbA1c, not GA, of the active group was significantly higher than that of the in-
active group (p=0.020). In addition, the optimal cut-off value of HbA1c was set to 5.6, and the patients with HbA1c ≥5.6 were 
found to have a 3.3 times higher risk of active AS than those without. Conclusion. HbA1c was significantly correlated with 
ASDAS-CRP, and could be a useful marker to reflect ASDAS-CRP in AS patients without medical conditions affecting the gly-
cated protein levels. (J Rheum Dis 2018;25:131-139)
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INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory 
disease that has characteristics of both articular and ex-
tra-articular manifestations ranging from inflammatory 
back pain to uveitis [1]. Before the era of biological dis-
ease modifying anti-rheumatic drugs (bDMARDs), the 
primary goal of therapeutic strategies for AS were to re-
duce pain and improve the daily activity through conven-
tional synthetic DMARDs (csDMARDs). Despite the use 
of csDMARDs, however, the progression of AS could not 
easily delayed or modified at all [2]. Meanwhile, bDMARDs 
can directly quench the inflammatory response of AS, and 
in turn, it can minimize AS progression at earlier phase 
and prevent its systemic complications [3]. Thus, if we 
can precisely assess the disease activity of AS and not 
miss the proper time to start bDMARDs, we may expect 
a good prognosis in AS patients. 
However, since the entity of AS is mainly characterized 
by localized inflammation, especially confined to axial 
joints, there have been discrepancies between conven-
tional inflammatory markers, including erythrocyte sed-
imentation rate (ESR) or C-reactive protein (CRP) and 
the disease activity of AS in a considerable number of pa-
tients [4]. In the clinical settings, Bath Ankylosing Spon-
dylitis Disease Activity Index (BASDAI) is the most wide-
ly used tool to assess the disease activity of AS for its 
convenience. But BASDAI has a limitation that it does not 
include physician’s assessment nor objective evidence of 
inflammation, because it consists of only patient-reported 
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items [5]. To complement it, a new composite index, 
Ankylosing Spondylitis Disease Activity Score (ASDAS), 
has been suggested. It adds objective laboratory findings 
including ESR and CRP to patient-reported items (ASDAS- 
ESR and ASDAS-CRP) [6]. However, so far, there has 
been no single serum marker to reflect the disease activity 
of AS. 
Glycated proteins, which are produced through non-en-
zymatic reaction between sugars and free amino groups 
of proteins, can be formed in diverse pathological or phys-
iological conditions such as diabetes mellitus and inflam-
mation [7,8]. Glycated hemoglobin (HbA1c) and glycated 
albumin (GA) are glycated proteins and they can identify 
plasma glucose concentration in different follow-up dura-
tions [9,10]. Moreover, HbA1c and GA were recently re-
ported that they could reflect and monitor the inflam-
matory burdens [11,12]. But there has been no report re-
garding the association of HbA1c and GA with the disease 
activity of AS yet. Hence, in this study, we investigated 
whether glycated proteins, HbA1c and GA, are adjunctive 
markers to be well correlated with ASDAS-ESR and 
ASDAS-CRP in AS patients, who had normal laboratory 
results including HbA1c, GA and fasting glucose, and 
who had no medical history of abnormal glucose metabo-
lism and other medical conditions affecting glycated pro-
tein levels.
MATERIALS AND METHODS
Patients
We consecutively enrolled 94 patients with AS in this 
study from March 2015 to October 2015 according to the 
inclusion criteria as follows: (i) patients who fulfilled 
modified New York criteria for AS [13], and who had been 
classified at the Division of Rheumatology, Yonsei Uni-
versity College of Medicine, Severance Hospital; (ii) pa-
tients who had no medical history which can influence on 
the turnover of albumin and red blood cell, including oth-
er autoimmune diseases other than AS [12], diabetes 
mellitus [14], thyroid disease [15], nephrotic syndrome 
[16], chronic liver diseases [17], and haemolytic anaemia 
[18] identified by 10th revised international classification 
of diseases; (iii) patients who had never received medi-
cations for those diseases searched by the Korean Drug 
Utilization Review system; (iv) patients who had no con-
current infection and malignancy to enhance acute re-
actants levels; (v) patients who gave informed consent to 
their participation; (vi) patients who took clinical assess-
ment by independent physician on the same day of labo-
ratory tests; (vii) patients having laboratory results ful-
filling the following criteria: fasting glucose ＜126 
mg/dL, HbA1c ＜6.5%, platelet count ＞150,000/mm3, 
creatinine ≤1.3 mg/dL or estimated glomerular filtration 
rate by the Chronic Kidney Disease Epidemiology 
Collaboration ＞60 mL/min/1.73 m2, serum albumin ≥
3.5 mg/dL, alkaline phosphatase ≤115 IU/L, aspartate 
aminotransferase ≤40 IU/L, alanine aminotransferase ≤
40 IU/L. We excluded 7 of 94 patients due to medical con-
ditions and 11 of the rest due to the laboratory results ex-
ceeding normal values. Finally, we included 76 patients 
with AS in this study. Demographic features included age, 
gender, smoking history, body mass index (BMI), the fol-
low-up duration and the use of glucocorticoid and anti-tu-
mour necrosis factor agents. This study was approved by 
the Institutional Review Board of Severance Hospital (no. 
4-2015-0802). Informed consent was obtained from all 
patients.
Laboratory tests and disease activity assessment
HbA1c levels were measured via automated COBAS 
INTEGRA 800 (Roche Diagnostics, Mannheim, Germany). 
GA levels were measured using a Hitachi 7600-120 auto-
matic analyser (Hitachi, Tokyo, Japan) and an enzymatic 
method and an albumin detection reagent (Lucica GA-L; 
Asahi Kasei Pharma Co., Tokyo, Japan). We selected 
items of laboratory tests, which are routinely performed 
at each regular visit, as described in Table 1. ASDAS-ESR 
and ASDAS-CRP were also obtained by the equations as 
below: 0.08×Back Pain+0.07×Duration of Morning 
Stiffness+0.11×Patient Global+0.09×Peripheral Pain/ 
Swelling+0.29×  for ASDAS-ESR and 0.12×Back 
Pain+0.06×Duration of Morning Stiffness+0.11×Patient 
Global+0.07× Peripheral Pain/Swelling+0.58×Ln (CRP+ 
1) [6,19]. Also we assessed the disease activity of AS such 
as BASDAI [5], Bath Ankylosing Spondylitis Functional 
Index (BASFI) [20], and Bath Ankylosing Spondylitis 
Patient Global Score (BAS-G) [21].
Statistical analysis
All statistical analyses were conducted using the IBM 
SPSS package for Windows version 23.0 (IBM Co., 
Armonk, NY, USA). Continuous variables were expressed 
as median (interquartile range) or mean±standard 
deviation. Correlations between variables were determined 
by the Pearson rank test. Univariate analysis of the associ-
ation of variables with ASDAS-ESR and ASDAS-CRP was 
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Table 1. Baseline characteristics of patients with ankylosing 
spondylitis (n=76)
Variable Value
Demographic data 
  Age (yr) 39.0 (18.0) 
  Male gender    58 (76.3)
  Follow-up duration (yr) 5.0 (8.5) 
  Smoking    29 (38.2)
  BMI (kg/m2) 24.0 (5.0)
  HLA-B27    60 (78.9)
  Syndesmophyte formation    20 (26.3)
Laboratory results
  HbA1c (%) 5.5 (0.4)
  GA (%) 12.7 (1.5)
  Fasting glucose (mg/dL) 95.5 (12.8)
  ESR (mm/h) 19.0 (28.0)
  CRP (mg/L) 2.3 (5.9)
  Ferritin (mg/dL) 75.5 (70.0)
  White blood cell (/mm3) 7,325.0 (2,580.0) 
  Hemoglobin (g/dL) 14.9 (2.4)
  Platelet×103 (/mm3) 261.0 (69.5)
  Albumin (mg/dL) 4.4 (0.5)
  Blood urea nitrogen (mg/dL) 13.9 (4.4)
  Creatinine (mg/dL) 0.8 (0.2)
  Alkaline phosphatase (IU/L) 70.0 (26.0)
  Aspartate aminotransferase (IU/L) 21.0 (8.0)
  Alanine aminotransferase (IU/L) 18.0 (17.0)
  Total cholesterol (mg/dL) 188.0 (40.5)
  High density cholesterol (mg/dL) 53.0 (17.0)
  Low density cholesterol (mg/dL) 107.8 (24.4)
  Triglyceride (mg/dL) 96.0 (76.0)
Disease activity indexes
  ASDAS-ESR 2.2 (1.5)
  ASDAS-CRP 1.8 (1.4)
  BASDAI 3.3 (2.4)
  BAS-G 3.0 (3.3)
  BASFI 1.3 (2.6)
Medications
  Glucocorticoid use    7 (9.2)
  Methotrexate use    5 (6.6)
  Sulfasalazine use    39 (51.3)
  Anti-TNF agents use    27 (35.5)
Values are expressed as median (interquartile range, IQR) or 
number (%). BMI: body mass index, HLA: human leukocyte 
antigen, HbA1c: hemoglobin A1c, GA: glycated albumin, 
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, 
ASDAS: ankylosing spondylitis disease activity score, BASDAI: 
bath ankylosing spondylitis disease activity index, BAS-G: 
bath ankylosing spondylitis patient global score, BASFI: bath 
ankylosing spondylitis disease activity functional index, TNF: 
tumour necrosis factor.
performed using linear regression test. Standardized cor-
relation coefficient was assessed by a multivariate linear 
regression test using variables with significant differ-
ences on univariate analysis. The chi-square test and 
Fisher’s exact test were used for significant differences of 
categorical data between the two groups. We used Student’s 
t-test or Mann-Whitney U-test to compare continuous 
variables between the two groups. p-values less than 0.05 
were considered statistically significant.
RESULTS
Baseline characteristics of patients with ankylosing 
spondylitis
Baseline characteristics are summarized in Table 1. The 
median age of patients was 39.0 years old (58 men and 18 
women), and the median follow-up duration was 8.1 
years. Twenty nine of patients (38.2%) had smoking his-
tory, and the median BMI was 24.0 kg/m2. Human leuko-
cyte antigen B27 was detected in 60 patients (79.0%). 
The median HbA1c, GA and fasting glucose were 5.5%, 
12.7% and 95.5 mg/dL, respectively. The median ESR and 
CRP were 19.0 mm/hour and 2.3 mg/L. The median 
ASDAS-ERS and ASDAS-CRP were 2.2 and 1.8, and the 
median BASDAI, BAS-G and BASFI were assessed as 3.3, 
3.0 and 1.3, respectively. Seven patients had ever received 
glucocorticoid and 27 patients had done anti-tumor ne-
crosis factor (TNF) agents. 
Correlation of between glycated proteins and dis-
ease activity
We evaluated the correlation of HbA1c and GA with the 
disease activity indices of AS. HbA1c was remarkably cor-
related with GA, fasting glucose and BMI (r=0.400, 
r=0.405 and r=0.227, p＜0.005 for all). HbA1c showed 
significantly positive correlation with ASDAS-CRP (r= 
0.315, p=0.006), but not ASDAS-ERS (r=0.220, p=0.560). 
Also, HbA1c was meaningfully correlated with BASDAI 
(r=0.226) and BAS-G (r=0.401), but not BASFI (r=0.124). 
On the other hands, GA exhibited no significant correla-
tion with any disease activity index of AS (Supplementary 
Table 1). 
Univariate and multivariate analyses of ASDAS-ESR 
and other variables
Univariate linear regression analysis revealed that 
ASDAS-ESR was positively correlated with white blood 
cell (r=0.266, p=0.020) and inversely correlated with he-
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Table 2. Univariate and multivariate analysis of ASDAS-ESR and other variables 
Variable
Univariate analysis Multivariate analysis
Regression
coefficient
(crude B)
Correlation
coefficient
(R=β)
p-value
Standardized 
β*
95% 
confidential 
interval
p-value
Demographic data 
  Age (yr)     0.013 0.172 0.136
  Follow-up duration (yr) −0.002 −0.011 0.923
  BMI (kg/m2)     0.003 0.013 0.910
Laboratory results
  HbA1c (%)     0.661 0.220 0.056 0.102 −0.298, 0.911 0.316
  GA (%)     0.069 0.105 0.368
  Fasting glucose (mg/dL)     0.001 0.011 0.923
  ESR (mm/h) N/A N/A N/A
  CRP (mg/L)     0.054 0.448 ＜0.001
  Ferritin (mg/dL) −0.002 −0.145 0.296
  White blood cell (/mm3)     0.120 0.266 0.020 0.266 0.028, 0.211 0.011
  Hemoglobin (g/dL) −0.229 −0.414 ＜0.001 −0.355 −0.316, −0.075 0.002
  Platelet×103 (/mm3)     0.003 0.206 0.074
  Serum albumin (mg/dL) −1.187 −0.394 ＜0.001 −0.195 −1.249, 0.075 0.081
  Blood urea nitrogen (mg/dL)     0.057 0.223 0.053
  Creatinine (mg/dL) −0.620 −0.104 0.373
  Alkaline phosphatase (IU/L)     0.009 0.181 0.121
  Aspartate aminotransferase (IU/L)     0.004 0.029 0.805
  Alanine aminotransferase (IU/L)     0.004 0.040 0.734
  Total cholesterol (mg/dL)     0.003 0.109 0.350
  High density cholesterol (mg/dL)     0.005 0.078 0.569
  Low density cholesterol (mg/dL) −0.001 −0.040 0.765
  Triglyceride (mg/dL)     0.002 0.121 0.366
Medications
  Glucocorticoid use     0.350 0.106 0.364
  Methotrexate use −0.056 −0.015 0.901
  Sulfasalazine use     0.385 0.201 0.082
  Anti-TNF agents use  −0.140 −0.070 0.548
ASDAS: ankylosing spondylitis disease activity score, ESR: erythrocyte sedimentation rate, BMI: body mass index, HbA1c: 
hemoglobin A1c, GA: glycated albumin, CRP: C-reactive protein, TNF: tumour necrosis factor, N/A: not available. *CRP was not
included in multivariate analysis, because CRP is a variable closely correlated with ESR (ASDAS-ESR) in inflammation in order not
to confound the interpretation of statistical results. 
moglobin (r=−0.414, p＜0.001) and serum albumin (r=
−0.394, p＜0.001). ASDAS-ESR showed a tendency to 
correlate with Hb1AC, but it was not statistically sig-
nificant (r=0.220, p=0.056). ASDAS-ESR was not corre-
lated with GA (Table 2). We included HbA1c in multi-
variate analysis, because its p-value was almost near the 
statistical significance. However, on multivariate linear 
regression analysis, only white blood cell and hemoglobin 
were significantly correlated with ASDAS-ESR (β=0.266, 
p=0.011 and β=−0.355, p=0.002).
Univariate and multivariate analyses of ASDAS-CRP 
and other variables
Univariate linear regression analysis discovered that 
ASDAS-CRP was positively correlated with HbA1c (r= 
0.315, p=0.006) and white blood cell (r=0.288, p=0.012) 
and inversely correlated with haemoglobin (r=−0.241, 
p=0.036) and serum albumin (r=−0.262, p=0.022). 
ASDAS-CRP was not correlated with GA. On multiva-
riate linear regression analysis, HbA1c and white blood 
cell were still significantly correlated with ASDAS-CRP 
(β=0.234, p=0.033 and β=0.265, p=0.017) (Table 3). 
Also, we analyzed correlation between the use of medi-
HbA1c Reflects ASDAS-CRP
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Table 3. Univariate and multivariate analysis of ASDAS-CRP and other variables 
Variable
Univariate analysis Multivariate analysis
Regression
coefficient
(crude B)
Correlation
coefficient
(R=β)
p-value
Standardized 
β*
95% 
confidential 
interval
p-value
Demographic data 
  Age (yr) 0.013 0.164 0.158
  Follow-up duration (yr) 0.015 0.105 0.367
  BMI (kg/m2) 0.008 0.032 0.781
Laboratory results
  HbA1c (%) 0.972 0.315 0.006 0.234    0.060, 1.383 0.033
  GA (%) 0.091 0.135 0.244
  Fasting glucose (mg/dL) 0.004 0.037 0.750
  ESR (mm/h) 0.026 0.477 ＜0.001
  CRP (mg/L) N/A N/A N/A
  Ferritin (mg/dL) −0.003 −0.199 0.150
  White blood cell (/mm3) 0.133 0.288 0.012 0.265    0.022, 0.222 0.017
  Hemoglobin (g/dL) −0.137 −0.241 0.036 −0.204 −0.248, 0.016 0.084
  Platelet×103 (/mm3) 0.002 0153 0.186
  Serum albumin (mg/dL) −0.811 −0.262 0.022 −0.099 −1.030, 0.419 0.404
  Blood urea nitrogen (mg/dL) 0.027 0.104 0.373
  Creatinine (mg/dL) −0.243 −0.040 0.734
  Alkaline phosphatase (IU/L) 0.011 0.212 0.068
  Aspartate aminotransferase (IU/L) 0.015 0.098 0.402
  Alanine aminotransferase (IU/L) 0.014 0.145 0.213
  Total cholesterol (mg/dL) 0.004 0.119 0.307
  High density cholesterol (mg/dL) −0.012 −0.159 0.246
  Low density cholesterol (mg/dL) 0.002 0.069 0.609
  Triglyceride (mg/dL) 0.004 0.184 0.166
Medications
  Glucocorticoid use 0.147 0.044 0.707
  Methotrexate use 0.236 0.060 0.604
  Sulfasalazine use 0.349 0.180 0.120
  Anti-TNF agents use −0.325 −0.161 0.166
ASDAS: ankylosing spondylitis disease activity score, CRP: C-reactive protein, BMI: body mass index, HbA1c: hemoglobin A1c, 
GA: glycated albumin, ESR: erythrocyte sedimentation rate, TNF: tumour necrosis factor, N/A: not available. *ESR was not included
in multivariate analysis, because ESR is a variable closely correlated with CRP (ASDAS-CRP) in inflammation in order not to 
confound the interpretation of statistical results. 
cations and ASDAS indexes, there was no statistical sig-
nificance (Tables 2 and 3). 
Comparison of variables between patients with ac-
tive and inactive AS based on ASDAS-CRP ＞2.1 
When patients with AS had ASDAS-CRP ＞2.1, they can 
be considered to have high or very high disease activity. 
Since HbA1c showed a significant correlation with ASDAS- 
CRP, but not ASDAS-ESR, we divided patients into active 
(40 patients) and inactive (36 patients) groups, based on 
ASDAS-CRP ＞2.1. There were no significant differences 
in demographic data between the two groups. The mean 
HbA1c of patients in active group was significantly higher 
than that of patients in inactive group (5.6 vs. 5.4, p=0.020), 
but the mean GA did not differ between the two groups 
(Table 4). Patients in active group showed the higher 
mean ESR and white blood cell, whereas, than the lower 
mean hemoglobin and serum albumin than those in in-
active group (30.6 vs. 14.3, p＜0.001, 8,273.6 vs. 7,088.5, 
p=0.013, 14.0 vs. 15.0, p=0.008 and 4.3 vs. 4.5, p=0.016, 
respectively). The mean ASDAS-ESR, BASDAI and BAS-G 
in active group were significantly higher than those in in-
active group. On the other hand, the frequency of gluco-
corticoid, methotrexate, sulfasalazine and anti-TNF anti-
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Table 4. Comparison variables between patients with active and inactive ankylosing spondylitis based on ASDAS-CRP ＞2.1 
Variable Inactive AS (n=40) Active AS (n=36) p-value
Demographic data 
  Age (yr) 37.3±11.2 40.8±12.8 0.201
  Male gender     34 (85.0)    24 (66.7) 0.061
  Follow-up duration (yr) 7.7±6.4 8.0±7.4 0.824
  Smoking     14 (35.0)    15 (41.7) 0.055
  BMI (kg/m2) 24.5±4.0 23.9±4.0 0.526
  HLA-B27     30 (75.0)    30 (83.3) 0.374
Laboratory results
  HbA1c (%) 5.4±0.3 5.6±0.3 0.020
  GA (%) 12.7±1.2 13.0±1.7 0.395
  Fasting glucose (mg/dL) 97.7±9.8 95.9±9.7 0.414
  ESR (mm/h) 14.3±11.7 30.6±18.8 ＜0.001
  CRP (mg/L) N/A N/A N/A
  Ferritin (mg/dL) 107.7±69.4 75.3±73.1 0.100
  White blood cell (/mm3) 7,088.5±1,767.6 8,273.6±2,280.8 0.013
  Hemoglobin (g/dL) 15.0±1.4 14.0±1.9 0.008
  Platelet×103 (/mm3) 252.1±45.4 275.6±75.3 0.110
  Albumin (mg/dL) 4.5±0.3 4.3±0.3 0.016
  Blood urea nitrogen (mg/dL) 14.1±3.4 14.9±4.1 0.330
  Creatinine (mg/dL) 0.8±0.2 0.8±0.2 0.551
  Alkaline phosphatase (IU/L) 69.1±18.1 74.5±20.3 0.230
  Aspartate aminotransferase (IU/L) 20.5±7.1 21.6±5.7 0.442
  Alanine aminotransferase (IU/L) 19.7±10.1 21.7±9.5 0.398
  Total cholesterol (mg/dL) 189.7±28.3 194.0±31.6 0.534
  High density cholesterol (mg/dL) 53.4±8.6 50.7±15.8 0.425
  Low density cholesterol (mg/dL) 116.8±31.4 116.3±29.3 0.945
  Triglyceride (mg/dL) 95.5±39.3 113.4±49.1 0.129
Disease activity 
  ASDAS-ESR 1.8±0.6 3.1±0.8 ＜0.001
  ASDAS-CRP N/A N/A N/A
  BASDAI 2.5±1.2 4.5±1.7 ＜0.001
  BAS-G 2.5±1.7 4.7±2.2 ＜0.001
  BASFI 1.7±4.3 2.9±1.8 0.185
Medications
  Glucocorticoid use     2 (5.0)      5 (13.8) 0.181
  Methotrexate use     2 (5.0)    3 (8.3) 0.651
  Sulfasalazine use     19 (47.5)    20 (55.5) 0.258
  Anti-TNF antibody use     16 (40.0)    11 (30.6) 0.390
Values are expressed as mean±standard deviation or number (%). ASDAS: ankylosing spondylitis disease activity score, CRP: 
C-reactive protein, AS: ankylosing spondylitis, BMI: body mass index, HLA: human leukocyte antigen, HbA1c: hemoglobin A1c,
GA: glycated albumin, ESR: erythrocyte sedimentation rate, BASDAI: bath ankylosing spondylitis disease activity index, BAS-G: 
bath ankylosing spondylitis patient global score, BASFI: bath ankylosing spondylitis disease activity functional index, TNF: tumour
necrosis factor, N/A: not available. 
body uses did not show statistically significant difference 
between the two groups. 
On multivariate logistic regression analysis of these sig-
nificant variables, only white blood cell and hemoglobin 
were independently associated with high disease activity 
of AS based on ASDAS-CRP of 2.1 (odds ratio [OR]=1.442, 
95% confidential interval [CI]=1.067, 1.947, p=0.017, 
and OR=0.656, 95% CI=0.456, 0.940, p=0.022). The 
statistical significance of HbA1c disappeared on multi-
variate analysis (OR=4.132, 95% CI=0.704, 24.240, 
p=0.116) (Table 5). 
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Table 5. Multivariate logistic regression analysis using variables with statistical significance between patients with active and 
inactive ankylosing spondylitis based on ASDAS-CRP ＞2.1
Variable Odds ratio 95% confidence interval p-value
HbA1c (%) 4.132 0.704, 24.240 0.116
White blood cell (/mm3) 1.442 1.067, 1.947 0.017
Hemoglobin (g/dL) 0.656 0.456, 0.940 0.022
Albumin (mg/dL) 0.482 0.075, 3.086 0.441
ASDAS: ankylosing spondylitis disease activity score, CRP: C-reactive protein, HbA1c: hemoglobin A1c. 
DISCUSSION 
Glycated albumin is a clinical marker to predict for coro-
nary artery disease in type 2 diabetes patients, and it is 
well known as having correlation with high sensi-
tivity-CRP, TNF-alpha, and interleukin-6 level [22]. In 
the study using bovine serum albumin, it shows that in-
creased advanced glycation end-products which are rep-
resentative for glycated albumin in diabetic patients upre-
gulate thrombotic responses and deteriorate vessel ge-
ometry through constant disturbed shear stress in endo-
thelial cell [23]. Meanwhile, HbA1c is marker to reflect 
severity of coronary artherosclerosis in non-diabetic in-
dividuals, so it has association in lower albumin concen-
trations, increased concentration of CRP, fibrinogen and 
white blood cell level, and so on. It is because HbA1c re-
flects subclinical derangement in glucose metabolism 
caused by chronic inflammation though it has normal 
range [24].
In this study, we first investigated whether glycated pro-
teins, HbA1c and GA, are adjunctive markers to be well 
correlated with ASDAS-ESR and ASDAS-CRP. And we 
demonstrated that HbA1c was significantly correlated 
with ASDAS-CRP, and HbA1c could be a useful marker to 
reflect ASDAS-CRP in AS patients without medical con-
ditions affecting glycated protein levels. Meanwhile, 
HbA1c had a tendency to correlate with ASDAS-ESR, but 
it had no statistical significance (p=0.056). In addition, 
we found that HbA1c was correlated with BASDAI and 
BAS-G with statistical significance as well, but in the 
present study, we focused on the ASDAS-ESR and ASDAS- 
CRP containing objective laboratory results in their 
equations. In the real clinical settings, a majority of physi-
cians are measuring the levels of acute reactants, such as 
ESR and CRP, at each visit of patients of AS. However, 
most of them have no over-credulity to directly apply 
them to AS patients to reflect the disease activity, due to 
its low sensitivity and singularity in AS [25]. By contrast, 
BASDAI, BAS-G and BASFI are not objectively reliable 
due to their limited subjective items [5]. ASDAS-ESR and 
ASDAS-CRP are likely to overcome these limitations by 
adding objective laboratory results to patient-reported 
forms. In this regard, our study might be valuable in 
terms of discovering a convenient serum marker to reflect 
ASDAS-CRP in AS patients, who had normal laboratory 
results including HbA1c, GA and fasting glucose, and 
who had no medical history of abnormal glucose metabo-
lism and other medical conditions affecting glycated pro-
tein levels. 
In our previous study, we consecutively enrolled 205 pa-
tients with rheumatoid arthritis (RA) and analysed their 
data. And we concluded that GA increased along with the 
disease activity in rheumatoid factor positive RA patients, 
and furthermore, GA was an independent and potential 
predictor of active RA, comparable with ESR and CRP 
[12]. However, in this study, we failed to elucidate that 
GA was correlated with the disease activity indices of AS. 
GA is a newly suggested parameter for the status of glu-
cose metabolism, and it has an advantage in that it can re-
flect the relatively short-term alternations in plasma glu-
cose concentration, compared to HbA1c, whereas, HbA1c 
can reflect the status of glucose metabolism over 60 days 
ago [9,10,26]. In addition, the disease progression and 
the fluctuation of inflammatory burdens of RA are more 
changeable than those of AS due to its low sensitivity in 
AS diagnosis and disease activity assessment [25,27]. 
Our results also demonstrated that HbA1c was not corre-
lated with CRP (r=0.023, p=0.842) and ESR (r=0.201, 
p=0.081). But HbA1c was well correlated with ASDAS-CRP, 
which can reflect the accumulative outcome of the alter-
ation in inflammatory burdens over time. In this regard, 
we first revealed that HbA1c can reflect subtle impaired 
glucose tolerance and metabolic alterations provoked by 
subclinical inflammatory burdens more clearly than GA 
in patients with AS, unlike RA. 
Although there was no statistical significance on multi-
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Figure 1. Optimal cut-off values of HbA1c to reflect active an-
kylosing spondylitis. Active ankylosing spondylitis in patients 
having HbA1c ≥5.6 was identified more often than in those 
having HbA1c ＜5.6 (62.9% vs. 34.1%, p=0.012). Patients 
having HbA1c more than 5.6 showed significantly enhanced 
risk of active AS than those having not (RR=3.264). ASDAS: 
ankylosing spondylitis disease activity score, CRP: C-reactive 
protein, RR: relative risk, HbA1c: hemoglobin A1c, AS: anky-
losing spondylitis.
variate analysis, HbA1c did show a significant difference 
between active and inactive AS groups based on ASDAS- 
CRP of 2.1 on univariate analysis (p=0.020). We as-
sumed that this result might result from the relatively low 
median and mean of ASDAS-CRP as 1.8 and 2.0, which 
are below the cut-off of 2.1. With this reason, we set the 
optimal cut-off values of HbA1c to reflect active AS by cal-
culating the area under the receiver operator character-
istic curve (AUROC) and selection to maximize the sum 
of sensitivity (0.611) and specificity (0.675). In addition, 
the relative risk (RR) of the cut-off value of HbA1c for in-
creased disease activity of AS was analysed using con-
tingency tables and the chi-square test. And we found 
that 5.6 of HbA1c (AUROC=0.669, 95% CI=0.547, 
0.791, p=0.011) was the optimal cut-off value good enough 
to reflect active AS. When we divided 76 patients with AS 
into two groups based on the calculated optimal cut-off 
value of HbA1c, active AS in patients having HbA1c more 
than 5.6 was identified more often than in those having 
HbA1c below 5.6 (62.9% vs. 34.1%, p=0.012). Moreover, 
patients having HbA1c more than 5.6 showed sig-
nificantly enhanced risk of active AS than those having 
not (RR=3.264, 95% CI=1.273, 8.369) (Figure 1). If we 
are able to enrol the larger number of AS patients, we 
could validate the statistical power of the optimal cut-off 
value of HbA1c to easily and conveniently categorise ac-
tive AS or inactive AS in non-diabetic patients.
Previous studies have reported that sulfasalazine and 
methotrexate treatments can affect HbA1c levels [28,29], 
so we did univariate regression analysis between these 
medicines use and HbA1c, but we cannot find statistical 
significance (data now shown). 
The strength of this study is that we first demonstrated 
that HbA1c was significantly correlated with ASDAS-CRP, 
and HbA1c could be a useful marker to reflect ASDAS- 
CRP in AS patients without medical conditions affecting 
glycated protein levels. Furthermore, we could set the op-
timal cut-off value of HbA1c at 5.6, and we elucidated that 
patients having HbA1c more than 5.6 could have en-
hanced risk of active AS 3.3 times as high as those having 
not. 
We also had several issues: first, our study was a cross- 
sectional study; second, we did not measure the parame-
ters more directly related to HbA1c level, such as insulin 
resistance or intramural thickness; third, we could not 
perform sub-group analysis according to anti-hyper-
tension and anti-dyslipidaemia agents, which can worsen 
or improve insulin resistance or beta-cell functions 
[30,31]. If future studies can serially measure not only 
HbA1c, but also the parameters directly related to HbA1c 
level, they could provide a dynamic correlation between 
HbA1c and disease activity of AS. In conclusion, we here-
in showed that HbA1c was significantly correlated with 
ASDAS-CRP, and HbA1c could be a useful marker to re-
flect ASDAS-CRP in AS patients without medical con-
ditions affecting glycated protein levels. Furthermore, we 
elucidated that patients having HbA1c more than 5.6 
could have enhanced risk of active AS 3.3 times as high as 
those having not.
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Supplementary Table 1. Correlation among variables related to glucose metabolism and disease activity of ankylosing spondylitis
(n=76)
BMI HbA1c GA Fasting glucose ASDAS-ESR ASDAS-CRP BASDAI BAS-G
BMI     1
HbA1c     0.227* 1
GA −0.268* 0.400* 1
Fasting glucose     0.331* 0.405* 0.186 1
ASDAS-ESR     0.013 0.220 0.105 0.011 1
ASDAS-CRP     0.032 0.315* 0.135 0.037 0.792* 1
BASDAI     0.019 0.226* 0.192 0.010 0.719* 0.774* 1
BAS-G     0.039 0.401* 0.221 0.166 0.568* 0.617* 0.655* 1
BASFI −0.118 0.124 0.111 0.013 0.376* 0.322* 0.211 0.279*
BMI: body mass index, HbA1c: haemoglobin A1c, GA: glycated albumin, ASDAS: ankylosing spondylitis disease activity score,
BASDAI: Bath ankylosing spondylitis disease activity index, BAS-G: Bath ankylosing spondylitis patient global score, BASFI: Bath 
ankylosing spondylitis disease activity functional index. *p＜0.05.
    
